​

Relay Therapeutics (RLAY) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RLAY Stock Forecast

Relay Therapeutics (RLAY) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $19.40, with a high of $25.00 and a low of $16.00. This represents a 643.30% increase from the last price of $2.61.

- $5 $10 $15 $20 $25 High: $25 Avg: $19.4 Low: $16 Last Closed Price: $2.61

RLAY Stock Rating

Relay Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 1 Strong Buy (9.09%), 10 Buy (90.91%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 10 1 Strong Sell Sell Hold Buy Strong Buy

RLAY Price Target Upside V Benchmarks

TypeNameUpside
StockRelay Therapeutics643.30%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--6
Avg Price Target--$18.67
Last Closing Price$2.61$2.61$2.61
Upside/Downside--615.33%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25571--13
Mar, 25571--13
Feb, 25571--13
Jan, 25571--13
Dec, 24571--13
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 16, 2024Robert BurnsH.C. Wainwright$19.00$7.60150.00%627.97%
Sep 10, 2024Akash TewariJefferies$16.00$9.5168.24%513.03%
Sep 09, 2024Peter LawsonBarclays$17.00$9.5178.76%551.34%
Sep 04, 2024Jason GerberryBank of America Securities$20.00$6.41212.01%666.28%
May 10, 2024Peter LawsonBarclays$15.00$6.68124.55%474.71%
May 06, 2024Matt BieglerOppenheimer$25.00$7.04255.11%857.85%
Apr 20, 2023Akash TewariJefferies$12.50$12.351.21%378.93%
Feb 03, 2023Oppenheimer$33.00$22.7644.99%1164.37%
Sep 30, 2022Peter LawsonBarclays$23.00$23.14-0.61%781.23%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 14, 2024H.C. WainwrightBuyBuyhold
Sep 16, 2024H.C. WainwrightBuyBuyhold
Sep 09, 2024OppenheimerBuyPerformdowngrade
Sep 09, 2024BarclaysOverweightOverweighthold
Sep 04, 2024Bank of America SecuritiesBuyBuyhold
Aug 07, 2024OppenheimerBuyBuyhold
Jul 17, 2024JMP SecuritiesUnderperformUnderperformhold
Jun 07, 2024Cowen & Co.BuyBuyhold
Jun 07, 2024OppenheimerMarket OutperformMarket Outperformhold
May 10, 2024OppenheimerMarket OutperformMarket Outperformhold

Financial Forecast

EPS Forecast

$-15 $-11 $-7 $-3 $1 $5 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.15$-5.22$-2.27$-2.79$-2.36----
Avg Forecast$-4.81$-3.69$-2.74$-2.83$-2.52$-2.64$-2.55$-2.48$-1.68
High Forecast$-4.01$-3.08$-0.68$-2.76$-2.29$-2.20$-1.85$-1.99$0.34
Low Forecast$-5.94$-4.55$-11.03$-2.93$-2.71$-3.21$-3.01$-2.80$-4.72
Surprise %-76.09%41.46%-17.15%-1.41%-6.35%----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$82.65M$3.03M$1.38M$25.55M$10.01M----
Avg Forecast$38.75M$6.41M$4.46M$24.30M$15.08M$3.52M$20.47M$24.95M$152.86M
High Forecast$45.73M$7.57M$14.83M$30.45M$48.43M$8.39M$48.83M$25.85M$364.65M
Low Forecast$33.82M$5.60M$1.88M$1.17M$8.07M$268.42K$1.56M$24.06M$11.67M
Surprise %113.30%-52.76%-69.02%5.13%-33.64%----

Net Income Forecast

$-750M $-590M $-430M $-270M $-110M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-49.01M$-496.81M$-254.26M$-341.97M$-337.71M----
Avg Forecast$-589.59M$-579.15M$-258.70M$-341.97M$-306.66M$-331.40M$-297.78M$-293.44M$-206.34M
High Forecast$-492.14M$-463.32M$-206.96M$-273.58M$-280.65M$-269.85M$-226.94M$-243.93M$41.42M
Low Forecast$-727.58M$-694.98M$-310.43M$-410.37M$-332.66M$-392.94M$-368.62M$-342.95M$-577.98M
Surprise %-91.69%-14.22%-1.71%-10.13%----

RLAY Forecast FAQ

Is Relay Therapeutics stock a buy?

Relay Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 1 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Relay Therapeutics is a favorable investment for most analysts.

What is Relay Therapeutics's price target?

Relay Therapeutics's price target, set by 11 Wall Street analysts, averages $19.4 over the next 12 months. The price target range spans from $16 at the low end to $25 at the high end, suggesting a potential 643.30% change from the previous closing price of $2.61.

How does Relay Therapeutics stock forecast compare to its benchmarks?

Relay Therapeutics's stock forecast shows a 643.30% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Relay Therapeutics over the past three months?

  • April 2025: 38.46% Strong Buy, 53.85% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 38.46% Strong Buy, 53.85% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 38.46% Strong Buy, 53.85% Buy, 7.69% Hold, 0% Sell, 0% Strong Sell.

What is Relay Therapeutics’s EPS forecast?

Relay Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.64, marking a 11.86% increase from the reported $-2.36 in 2024. Estimates for the following years are $-2.55 in 2026, $-2.48 in 2027, and $-1.68 in 2028.

What is Relay Therapeutics’s revenue forecast?

Relay Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $3.52M, reflecting a -64.86% decrease from the reported $10.01M in 2024. The forecast for 2026 is $20.47M, followed by $24.95M for 2027, and $152.86M for 2028.

What is Relay Therapeutics’s net income forecast?

Relay Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-331M, representing a -1.87% decrease from the reported $-338M in 2024. Projections indicate $-298M in 2026, $-293M in 2027, and $-206M in 2028.